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Abstract
Reliability of laboratory results is determined by the ratio of incorrect results expected in long-term. Sigma is a measure of defect ratio, therefore 
long-term Sigma is a measure of the reliability of laboratory results. Commonly, long-term Sigma is estimated based on the short-term Sigma. The 
Six Sigma methodology assumes that in long-term performances will shift up to 1.5 Sigma, and therefore the long-term Sigma is considered 1.5 Si-
gma less than short-term Sigma. Analytical performance in the medical laboratory is prone to shifts larger than 1.5 Sigma. Thus, the 1.5 Sigma shift 
assumed in the Six Sigma is not a correct estimate in the medical laboratory. On the other hand, in the medical laboratory statistical quality control 
procedure (SQC) is applied to detect and correct shifts. Since SQC can be planned to trap shifts of different sizes, the threshold set for SQC determines 
the defect rate expected for long-term. 
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Introduction
“Medicine is a science of uncertainty and an art of 
probability” - William Osler (1). It is the same with 
medical laboratory results, and the results cannot 
be of complete reliability; but must be of enough 
reliability to let clinical decisions be made with low 
uncertainty and high probability. In the medical 
laboratory, the quality requirement is usually de-
fined in terms of total allowable error (TEa). Results 
that contain analytical errors that exceed TEa are 
considered incorrect results or defects. The relia-
bility of the results is determined by the ratio of in-
correct results produced by the assay method; i.e. 
the defect rate. The higher is the defect rate, the 
lower is the reliability and vice versa. For example, 
if a performance produces 5% incorrect results, 
then there is a 95% probability that any certain re-
sult is correct.
The defect rate can be determined either (a) di-
rectly by counting the defects, or (b) indirectly by 
calculations based on the Gaussian (normal) distri-
bution as the area under the curve beyond allow-
able limits. In 1986, the Motorola Company intro-
duced the Six Sigma concept as a quality manage-
ment technique (2). The Sigma score or Sigma 
metrics is the core measure in the Six Sigma meth-
odology and provides an indirect estimate of de-
fect rate (2). The term Sigma implies to the impre-
cision of the performance and presents the num-
ber of standard deviations between mean and tol-
erance limit (TL). The original industrial equation 
for calculating Sigma is: Sigma = (TL – |Shift|) / SD, 
where TL represents the maximum allowable de-
viation from the target value; Shift is the difference 
between mean and target value; and SD, standard 
deviation, represents the imprecision (2). There-
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fore, Sigma is the number of the SDs that fit in the 
distance between mean and the nearest TL to the 
mean.
Given the above equation, Sigma is in fact the nor-
malized z-value at the tolerance limit. Using the 
characteristics of the Gaussian curve, the z-value is 
converted to probability (P) corresponding to the 
ratio of defects. The higher the Sigma (z-value) is, 
the less area is out of allowable limits and thereby 
the lower is the defect rate. Using Sigma to estimate 
defect rate has gained a widespread acceptance 
and different tools and tables to convert Sigma to 
defect rate are presented in various sources (3).
Defect rate is usually presented as defects per mil-
lion (DPM) (or defects per million opportunities, 
DPMO). Usually, defect rate is determined via 
short-term evaluation, and then the expected 
long-term defect rate is estimated. In practice, the 
various influence factors affecting a performance 
cannot be completely evaluated in short-term 
evaluation, and therefore it is expected that the 
defect rate in the long-term is higher than the de-
fect rate observed in the short-term; therefore the 
quality that can be assured for the long-term is es-
timated less than the quality observed in the 
short-term. Based on the Six Sigma methodology, 
short-term Sigma is determined from short-term 
evaluation; a figure of 1.5 is subtracted from the 
calculated Sigma to estimate the long-term Sigma; 
and then the long-term Sigma is used to calculate 
the long-term defect rate (2). This approach to cal-
culating the long-term defect rate is usually ap-
plied in the medical laboratory for the estimation 
of the defect rate of analytical phase. This paper is 
going to argue this application and show that the 
long-term defect rate in the analytical phase in the 
medical laboratory is dependent on the capability 
of the quality control procedures; and therefore, 
the reliability of the results in long-term is deter-
mined by the threshold set for the control proce-
dures.
Sigma of analytical phase
The Six Sigma concept has been applied in differ-
ent industries including health care. Since in the 
medical laboratory the defect rate is reflecting the 
reliability of the results, Sigma value can provide a 
good measure of the reliability of laboratory re-
sults. In recent years, the Six Sigma concept has 
gained increasing application in the medical labo-
ratory; for example, as a valuable tool in evaluat-
ing the quality of analytical performance, planning 
appropriate quality control procedures, and im-
proving the quality of testing process (4). 
In the medical laboratory, defect is defined as an 
erroneous result, which differs from its corre-
sponding true value more than TEa. Given the 
terms ‘tolerance limit’ and ‘shift’ used in the indus-
trial Sigma equation are respectively analogous to 
the TEa and bias of the analytical performance in 
the medical laboratory, J. O. Westgard adapted the 
industrial Sigma equation and introduced the fol-
lowing Sigma equation for laboratory application: 
Sigma = (TEa – |B|) / SD, where B is bias, and SD is 
the standard deviation (4). Using this equation, the 
ratio of incorrect results, or the analytical defect 
rate resulting from combined effects of bias and 
imprecision, can be estimated. The Sigma value as 
the z-value of the distribution at TEa is used for 
calculating the analytical defect rate: Defect rate = 
P (z > Sigma), where P is the probability that re-
sults falls out of TEa limits; i.e. the ratio of incorrect 
results or defect rate. With unbiased performanc-
es, the two-sided probability is considered, and 
the areas out of both TEa limits are summed to de-
termine defect rate. With biases of ≥ 1 SD, the one-
sided probability is considered, and the area out of 
the nearest TEa limit to mean represents the de-
fect rate (the area out of the farthest TEa limit is 
neglected). Figure 1 shows the defect rate for a bi-
ased method. For the sake of ease, hereinafter in 
this paper defect rates are calculated using one-
sided probability. For example, with a TEa of 7, a 
bias of 1 and SD of 2, Sigma = (7 – 1) / 2 = 3. The 
Defect rate = P (z > 3) = 0.001349 ≈ 1350 DPM.
Short-term defect rate versus long-term 
defect rate
Ideally, to determine the defect rate of a system, it 
must be evaluated for a substantially long period; 
preferably for the whole lifetime of the system. 
Given financial and time constraints, in practice 
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the system is evaluated during a short period, de-
fect rate is calculated from the short-term data, 
and then it is decided what defect rate is expected 
for long-term performance (2). If there were a 
100% certainty that the performance observed in 
short-term would be completely stable in future, 
then it could be expected that the long-term de-
fect rate is exactly the same as observed in the 
short-term (2). In practice, the systems tend to shift 
away from the stable performance, and, on the 
other hand, it is impossible to detect shifts instant-
ly; therefore, it is expected that in long-term the 
defect rate is greater than short-term (2,5).
By convention established at Motorola, where the 
Six Sigma program originated, the Sigma level is 
adjusted by 1.5 sigma to recognize the tendency 
of processes to shift over the long term (3). It is as-
sumed that in long-term there will be unpreventa-
ble shifts of different sizes - from zero to 1.5 SD - 
that will return to stable state spontaneously. The 
1.5 SD shift is the worst case and the maximum 
decrease in quality that is expected for long-term. 
Given the worst case of 1.5 SD shift, Sigma expect-
ed for long-term is calculated as Sigma(long-term) = 
Sigma(short-term) - 1.5. For example, with a short-term 
bias of 1 and SD of 2 obtained from a method vali-
dation experiment, and TEa of 9, the calculation is 
as follows:
Sigma(short-term) = (9 – 1) / 2 = 4
Defect rate(short-term) = P (z > 4) 
= 0.0000317 ≈ 32 DPM
and
Sigma(long-term) = Sigma(short-term) – 1.5 = 2.5
Defect rate(long-term) = P (z > 2.5) 
= 0.006209 ≈ 6200 DPM.
Meaning, based on the Six Sigma convention, with 
an observed quality of 4 Sigma (32 DPM) in short-
term, the expected quality for long-term is 2.5 Sig-
ma (6200 DPM). In this example, the 32 DPM is the 
error ratio that has occurred in past, and 6200 DPM 
is the maximum error ratio that is expected for fu-
ture. In other words “the 1.5 Sigma shift indicates 
that if you intend to have 6200 DPM over the long 
term, the process must be more capable than the 
2.5 Sigma in order to accommodate instabilities or 
process shifts that occur over time” (3). Note that 
this does not mean that the long-term defect rate 
for this example will always be 6200 DPM; but in 
long-term there will be shifts from zero to 1.5 SD; 
consequently the long-term defect rate will be be-
tween 32 DPM (for the shift of zero) and 6200 DPM 
(for the shift of 1.5 SD). When it is to assure the end 
user, the worst case scenario, i.e. the quality of 
6200 DPM, is considered.
Sigma tables are constructed considering the as-
sumed 1.5 Sigma shit. Table 1 shows an example 
Sigma table in which the defect rate presented for 
e.g. a short-term Sigma of 4 is 6200 DPM that is cal-
culated as P (z > 2.5) instead of P (z > 4) to consider 
1.5 Sigma shift over long-term (3).
Long-term defect rate of analytical 
performance in medical laboratory 
Concerning medical laboratory, it is worthy to ask: 
is 1.5 SD the maximum shift expected for analyti-
Figure 1. A schematic representation of defect rate resulting 
from bias and imprecision. Sigma value is the distance between 
mean and the nearest allowable total error (TEa) limit present-
ed as multiples of standard deviation (SD). Defect rate is the 
area out of TEa limit. Here, the method is significantly biased, 
and therefore the one-sided probability is considered (the tail 
out of – TEa limit is very thin and is neglected).  
TEa TEa
Defect rate =
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cal performance? And, do the shifts return back to 
the stable state spontaneously?  
The limitation with the assumed 1.5 SD shift is that 
it is only a rule of thumb and “may or may not be 
an accurate estimate of the actual long-term insta-
bility of your process” (3). In fact, “the 1.5 value is a 
source of criticism in the literature because of its 
arbitrary (empirical) nature. (…) It is just a way of 
stating that processes are not stable forever, and 
this behaviour should be modelled somehow. This 
choice has proven to be a useful way to think 
about process performance." (2). The real world 
performances are prone to shifts substantially 
larger than 1.5 SD that are not corrected sponta-
neously. This is the case with the analytical perfor-
mance in the medical laboratory. Analytical per-
formance in the medical laboratory can be affect-
ed by various error sources causing shifts signifi-
cantly larger than 1.5 SD, and in addition, there is 
no guarantee that the shifts will be corrected 
spontaneously. Therefore, the 1.5 SD can “not be 
an accurate estimate of the actual long-term insta-
bility” of analytical performance in the medical 
laboratory (3). On the other hand, since the shifts 
are not reversed by themselves, control proce-
dures are needed to detect and correct instabili-
ties before affecting patient safety (5).  
A variety of statistical quality control (SQC) plan-
ning tools have been developed to detect shifts 
from the stable performance. The detection ability 
of SQC procedures is presented in power graphs in 
which probability of rejection is plotted versus the 
size of the error. Figure 2 is an example power 
graph for detecting the systematic error, SE. The 
probability of rejection or error detection (Ped) for 
SQC procedures is depended on the number of 
controls (N), the width of rejection borders, and 
the rules for interpreting quality control (QC) re-
sults. High-sensitive SQCs such as multi-rules with 
N of 4 to 6 can detect small shifts with a high Ped, 
while low-sensitive SQCs such as single rules with 
N of 1-2 can only detect large shifts with a high 
Ped (5). 
Given different capabilities of SQCs for detecting 
shifts, applying different SQCs to the same perfor-
mance leads to assuring different defect rates for 
Figure 2. An example power graph for detecting the system-
atic error (SE). The characteristics of the statistical quality con-
trol (SQC) procedures in Table 2 are presented in this figure. The 
probability for rejection (P) is plotted on the y-axis vs. the size 
of systematic error on the lower x-axis (as multiples of SD) and 
vs. the Sigma on the upper x-axis. Power curves (top to bottom) 
correspond to SQC procedures in the key at the right (4). Pfr - 
the probability of false rejection. Ped - the probability of error 
detection. N - number of quality control material assayed per 
run. R - number of runs through which the SQC rule is interpret-
ed. (The figure is produced by EZ Rules v.3 software. Westgard 
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690,000 1 - 0.5
DPM – defects per million. The defect rates are calculated 
after subtracting 1.5 from short-term Sigma to present the 
defect rate that is expected for long-term performance (2).  
Table 1. Example of Sigma table 
long-term.  Meaning, in obvious contrast to the Six 
Sigma methodology, the expected maximum 
long-term shift is not the arbitrarily assumed 1.5 
Sigma, but it is depended on the capability of the 
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applied SQC; the less sensitive is the SQC, the larger 
is the shift that goes on undetected. Therefore, re-
ferring to usual Sigma tables (e.g. Table 1) for deter-
mining long-term defect rate will be misleading.
In laboratory application of Sigma, it will be help-
ful that the terms "short-term Sigma" and "long-
term Sigma" be respectively considered as "Ob-
served Sigma" and "Assured Sigma":
•	 Observed Sigma: Sigma calculated from short-
term data, e.g. from method validation experi-
ment;
•	 Assured Sigma: The least expected Sigma for 
long-term, that is depended on the capability 
of the applied SQC to detect shifts.
As extreme examples, with a very loose SQC, even 
very large shifts would go on without being de-
tected and therefore maximum defect rate ex-
pected for long-term would be very larger than 
short-term. On the other hand, with a very power-
ful SQC that can detect very small shifts instantly, 
maximum defect rate expected for long-term is 
approximately the same as short-term.
In practice, there is no practical SQC to catch small 
shifts instantly, and therefore, the quality assured 
for long-term will always be somewhat less than 
the quality observed in short-term. The maximum 
decrease in Sigma expected for long-term is deter-
mined by the size of the shift that is needed for 
SQC to reach a high Ped. Although it is ideal to ap-
ply SQCs with Ped = 100%, such SQCs will increase 
the probability of false rejection (Pfr). In practice, 
SQCs are planned so that a Ped ≥ 90% is achieved 
while keeping Pfr ≤ 5% (5). The shift size needed 
for SQC to reach a Ped = 90% is called QC budget 
(5). QC budget is the Sigma consumed by SQC; de-
noted as Sigma(SQC). Thus, the least Sigma expect-
ed for long-term can be calculated as:
Sigma(Assured) = Sigma(Obsserved) – Sigma(SQC).
In the medical laboratory, when establishing a 
method, imprecision and bias are first determined 
via short-term method validation experiments (usu-
ally in 20 days) and then short-term Sigma is calcu-
lated (5). Thereafter, periodically (e.g. every 3 
months) imprecision is revised using internal QC 
data, and bias is revised using external QC data (5). 
For example, if a method validation experiment has 
determined a bias of 0.5 and SD of 1, given TEa = 6,
Sigma(Observed) = (6 – 0.5) / 1 = 5.5
Defect rate(Observed) = P (z > 5.5) ≈ 0.02 DPM.
Here, the 0.02 DPM is the defect rate that has hap-
pened during the evaluation period, but the maxi-
mum defect rate that can be assured (expected) 
for long-term depends on the detection ability of 
the applied SQC. The rejection probability of, e.g., 
1:3s/2:2s/R:4s/4:1s N4 (the topmost SQC procedure 
in Figure 2) reaches 90% at approximately SE = 2.3 
SD. That is 2.3 SD of the Observed Sigma will be 
consumed before this SQC catches the shift; i.e. 
Sigma(SQC) = 2.3. If we apply this SQC to a 5.5 Sig-
ma method, the performance will be rejected by 
90% probability when the quality has decreased 
from 5.5 Sigma to 3.2 Sigma (5.5 – 2.3). Thus, by 
applying this SQC to a 5.5 Sigma performance, we 
can give assurance that the worst quality in long-
term is 3.2 Sigma corresponding to 690 DPM; cal-
culated as:
Sigma(Assured) = Sigma(Obsserved) – Sigma(SQC) = 
= 5.5 – 2.3 = 3.2
Defect rate(Assured) = P (z > 3.2) ≈ 690 DPM
Note that this does not mean that in long-term the 
defect rate will always be 690 DPM, but this is the 
worst defect rate that is expected to happen in 
long-term without being detected by the SQC.
If less sensitive SQCs are applied to this same 5.5 
Sigma method, shifts larger than 2.3 SD are need-
ed to reach 90% rejection probability. For exam-
ple, 1:3s/2:2s/R:4s N2 will reject the performance 
with 90% probability at SE = 3.1 SD (Figure 2), i.e. 
Sigma(SQC) = 3.1. With this SQC, the Assured Sigma 
is 2.4 (5.5 – 3.1) corresponding to 8200 DPM. To 
compare, based on the Six Sigma assumption (Ta-
ble 1), the worst expected scenario for a 5.5 Sigma 
performance in long-term is 4 Sigma correspond-
ing to 32 DPM which is very less than the defect 
rates calculated for the mentioned SQCs (690 DPM 
and 8200 DPM). 
https://doi.org/10.11613/BM.2018.020101 Biochem Med (Zagreb) 2018;28(2):020101 
  6
Bayat H. Assured Sigma versus observed Sigma
The long-term quality targeted/assured 
by SQC
Commonly it is expected that the laboratory re-
sults are at least 95% reliable (5). To provide such a 
reliability, the defect rate should be ≤ 5%. There-
fore, a defect rate of 5% (50,000 DPM) is consid-
ered as the maximum tolerable defect rate of 
long-term performance. Given this, a shift leading 
to more than 5% erroneous results is considered a 
medically important error or a critical error; such 
as a critical systematic error (SEcrit) calculated as 
SEcrit = [(TEa – |B|) /SD] – 1.65 (5). Here, the 1.65 
represents one-sided z-value for a 5% chance of 
producing erroneous results. The term (TEa – |B|) / 
SD is the same Sigma, and therefore the equation 
is shortened as SEcrit = Sigma(observed) – 1.65 (4). 
The SQC should be chosen so that it has a Ped ≥ 
90% at the SEcrit to give assurance that in long-
term the defect rate will not exceed 5%. Given a 
performance with 5% defect rate is equal to a Sig-
ma of 1.65, the common practice in SQC planning 
is to assure a long-term quality of 1.65 Sigma. In 
other words, an Assured Sigma of 1.65 is the target 
of common SQC procedures; as is reflected in the 
upper x-axis of the common power curves starting 
from 1.65 Sigma (Figure 2). It is of importance to 
note that this does not mean that in long-term the 
quality will always be 1.65 corresponding to 5% 
defect rate, but this is the worst case. Meaning 
that in the presence of SQC, there is a maximum 
chance of 5% for the results to be incorrect. 
For example, given the critical SE for a 6 Sigma 
method is 4.35 (i.e. 6 – 1.65), then the single rule 
1:3s N1 with a Ped = 90% at SE = 4.35 can provide 
an Assured Sigma of 1.65 for a method with Ob-
served Sigma of 6 (Figure 2). In comparison, a 
method with Observed Sigma of 4 will have a SE-
crit of 2.35 (i.e. 4 - 1.65), then the multi-rule 
1:3s/2:2s/R:4s/4:1s N4 with a Ped = 90% at SE = 2.35 
can provide an Assured Sigma of 1.65 for an Ob-
served Sigma of 4 (Figure 2). With lower Observed 
Sigmas, tougher SQCs are needed to provide the 
1.65 Assured Sigma. For example, to control a 3 
Sigma method a multi-rule such as 
1:3s/2of3:2s/2:2s/R:4s/3:1s/6:x N6 is needed. 
How to provide higher patient safety 
with high Sigma methods?
The improved quality of high Sigma methods can 
be devoted to two different issues: to facilitate SQC 
procedures (the laboratory achievement), and/or to 
assure higher levels of quality for the test results 
(the patients’ achievement). With a 5% threshold for 
SQC, the laboratory, in fact, gains more advantage 
than patients of high Sigma methods. Because high 
Sigma methods are controlled by cheap and easy 
single rule SQCs compared to low Sigma methods 
that must be controlled with tough multi-rule SQCs. 
To devote the superiority of high Sigma methods to 
patient safety, the SQC bar should be set higher 
aiming at assuring defect rates lower than 5%. Fig-
ure 3 and Table 2 represent different SQCs needed 
to provide different levels of Assured Sigma with an 
Observed Sigma of 6. A long-term defect rate of 5% 
(50,000 DPM) is easily assured by 1:3s N1. If it is de-
sired to assure a defect rate of 0.5% (5000 DPM), 
then z (P = 0.995; one-sided) = 2.58 and SQC must 
be planned to assure a long-term quality of 2.58 
Figure 3. Selecting statistical quality control (SQC) procedures 
for providing different levels of Assured Sigma for an Observed 
Sigma of 6. The arrows (left to right) represent critical system-
atic errors (SEcrit) of 2.28, 2.91, 3.42, and 4.35, which correspond 
to assured long-term defect rates of 0.01%, 0.5%, and 5%, re-
spectively. Pfr - the probability of false rejection. Ped - the prob-
ability of error detection. N - number of quality control material 
assayed per run. R - number of runs through which the SQC rule 
is interpreted. (The figure is produced by EZ Rules v.3 software. 



























































SEcrit = 6 – 3.72 = 2.28
SEcrit = 6 – 3.09 = 2.91
SEcrit = 6 – 2.58 = 3.42
SEcrit = 6 – 1.65 = 4.35
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Sigma; and therefore, SEcrit = Observed Sigma – 
2.58. With a target of 2.58 Sigma as the long-term 
quality, SEcrit for a 6 Sigma method is 6 – 2.58 = 
3.42. Here, the 1:3s N2 has a Ped close to 90% at SE = 
3.42, and can be applied to assure the long-term 
defect rate of 0.5%. It is of note that assuring a long-
term defect rate of ≤ 0.5% consumes 2 times more 
control material than assuring a defect rate of ≤ 5%. 
If the bar is set even higher to assure less than 0.1% 
defect rate (1000 DPM); then z (P = 0.999; one-sid-
ed) = 3.09, and SEcrit = 6 – 3.09 = 2.91. Providing an 
Assured Sigma of 3.09 with a 6 Sigma method 
needs applying 1:3s N4, which consumes 4 times 
more control material than assuring the long-term 
Sigma of 1.65. And finally, to assure less than 0.01% 
defect rate (100 DPM); z (P = 0.9999; one-sided) = 
3.72, SEcrit = 6 – 3.72 = 2.28, and SQC is 1:3s/2:2s/
R:4s/4:1s N4 which, in addition to higher expense 
and cumbersome, has a Pfr = 3%. As is seen, more 
stringent SQCs are needed to provide higher levels 
of Assured Sigma. Note that even with a very strin-
gent SQC such as 1:3s/2:2s/R:4s/4:1s N4, the long-
term defect rate is far higher than the arbitrary as-
sumption in Six Sigma (100 DPM vs. 3.4 DPM). Table 
3 compares the worst qualities expected from dif-
ferent SQCs with the worst qualities assumed in Six 
Sigma methodology for different Sigma perfor-
mances.
Desired long-term DPM Assured Sigma SEcrit SQC procedure
50,000 1.65 4.35 1:3s N1
5000 2.58 3.42 1:3s N2
1000 3.09 2.91 1:3s N4
100 3.72 2.28 1:3s/2:2s/R:4s/4:1s N4
Column 1 is the maximum defect rate that is desired, and column 2 is the corresponding Assured Sigma value.  Column 3 presents 
SEcrit for a 6 Sigma method calculated as 6 minuses Assured Sigma (e.g. for the last row: 6 - 3.72 = 2.28).  DPM - defects per million. 
SEcrit - critical systematic error.  SQC - statistical quality control. N - number of control materials assayed per run.
Table 2. Comparing statistical quality control procedures needed to assure different maximum defect rates with an observed sigma 
of 6
Table 3. The expected long-term defect rate for different short-term Sigmas
Observed/Short-term 
Sigma (Defect rate, 
DPM)*
Assured/Long-term Sigma (long term defect rate, DPM)
Six Sigma SQC1 SQC2 SQC3 SQC4 SQC5 SQC6 SQC7











































































DPM - defect per million. Column 1 presents Observed Sigma calculated from short-term evaluation data, and the defect rate. 
Column 2 presents the long-term defect rate assuming the arbitrary 1.5 Sigma shift assumed by Six Sigma.  Columns 3-9 present 
long-term defect rate expected with a probability of 90% when different SQCs are applied to control a certain Observed Sigma. 
SQC1 to SQC7 correspond to SQC procedures presented in Figure 2; SQC1: 1:3s/2:2s/R:4s/4:1s N4; SQC2: 1:3s N4; SQC3: 1:3s/2:2s/R:4s 
N2; SQC4: 1:2s N1; SQC5: 1:3s N2; SQC6: 1:2.5s N1; SQC7: 1:3s N1. Note that defect rates in column 3 are higher than corresponding 
defect rate in column 2, meaning that even SQC1 (the toughest SQC presented in Figure 2) cannot assure the long-term defect rate 
assumed by Six Sigma because a shift of 2.3 SD is needed for SQC1 to reach Ped = 90%, while the maximum shift assumed in Six 
Sigma is 1.5 SD.
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Discussion
Laboratory results, to be helpful in making correct 
medical decisions, must be of good reliability. The 
least reliability that can be attributed to the results 
is determined by the maximum defect rate ex-
pected for long-term performance. Practically it is 
not possible to determine the defect rate via long-
term evaluations, so methods are evaluated in 
short periods and then an assumption is made 
about the maximum defect rate that is expected 
in long-term.  
Based on Six Sigma, the worst case scenario is that 
long-term Sigma is 1.5 Sigma less than short-term 
Sigma. J. O. Westgard, who first introduced the 
Sigma equation for the medical laboratory appli-
cation, applies the Six Sigma approach for calcu-
lating the long-term defect rate (4). In the West-
gard approach, Sigma is calculated from the short-
term data of bias and imprecision, then to convert 
the calculated Sigma to long-term defect rate, Sig-
ma tables are consulted in which defect rates are 
not presented exactly for the calculated Sigma but 
for the “calculated Sigma – 1.5”.     
The Westgard approach to estimate the long-term 
defect rate is in compliance with the Six Sigma 
methodology, and does not consider the capability 
of the control process. In contrast to the Six Sigma 
assumption, analytical performance in the medical 
laboratory is prone to instabilities larger than 1.5 
Sigma that, in addition, do not spontaneously re-
turn to the stable state. Therefore, control proce-
dures are applied to detect shifts before affecting 
patient safety. Commonly, SQC procedures are 
planned to detect shifts that are large enough to 
produce more than 5% erroneous results (5). With a 
SQC goal of < 5% defect rate, irrespective of the ob-
served quality in short-term, the quality that is as-
sured for long-term is 1.65 Sigma. By sure, a high 
Sigma method when stable or in the case of shifts 
smaller than the size rejected by SQC, performs 
with a quality better than 1.65 Sigma. But there is 
no mean to determine the shift size at any certain 
moment; therefore, as long as the SQC has not re-
jected the performance we can only give the assur-
ance that the defect rate has not yet exceeded 5% 
corresponding to 1.65 Sigma. It is of importance to 
note that the improved quality of high Sigma 
methods can be devoted to facilitate SQC proce-
dures and/or to assure higher levels of quality for 
the test results. As long as the target of SQC is an 
Assured Sigma of 1.65, applying high Sigma meth-
ods does not add so much to patient safety be-
cause the improved Sigma is mostly devoted to 
easing the SQC procedure. If it is intended to im-
prove patient safety, SQC should aim at higher lev-
els of Assured Sigma; meaning applying more 
stringent SQCs. Woodworth et al. present an ex-
ample for the relationship between the long-term 
defect rate and the capability of the quality con-
trol procedure (6). Evaluating long-term defect 
rates expected for several HbA1c methods, they 
show that applying stringer SQCs leads to de-
creased number of erroneous results, and con-
clude that: “(Observed) Sigma values are directly 
related to the predicted probability of producing 
unreliable patient results during stable operation, 
while the maximum expected erroneous results 
during an out of control operation is determined 
by the SQC strategy used by the laboratory”. Thus, 
they recommend that evaluation of the SQC plan 
must be included in the process of estimating the 
expected risk of the analytical phase in long-term 
performance (6). The last edition of the Clinical 
and Laboratory Standards Institute (CLSI) C24 
guideline addresses how a laboratory’s QC prac-
tices affect the risk of patient harm in long-term 
performance (7).
Recently the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) Task 
Force on Implementation of HbA1c standardiza-
tion (TF-HbA1c) has set default risk levels of 2 Sig-
ma for routine laboratories and, to provide more 
reliable data to be used in providing clinical prac-
tice guidelines, 4 Sigma for laboratories perform-
ing clinical trials (8). This means that different lev-
els of Assured Sigma for routine and clinical trial 
applications should be instituted. Therefore, the 
same method when used in clinical trials should 
be controlled with a more stringent SQC than 
when used in routine laboratories. For example, 
with a 6 Sigma method, 1:2.5s N1 SQC is enough to 
provide the Assured Sigma of 2 in the routine ap-
plication while the multi-rule 1:3s/2:2s/R:4s/4:1s N4 
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must be applied to provide the Assured Sigma of 4 
in the clinical trial application.  
By sure, the ultimate goal of the quality assurance 
in the medical laboratory is to achieve the highest 
possible level of patients’ safety. If it is desired to 
provide high levels of Assured Sigma by simple 
SQC procedures, the Observed Sigma should be 
substantially greater than the desired Assured Sig-
ma to provide enough space needed for simple 
SQCs to reach a Ped ≥ 90%. For example, 1:3s N1, 
the simplest SQC in the collection presented in 
Figure 2, needs a 4.35 Sigma shift before it reaches 
Ped = 90%. Therefore, to apply this SQC, the Ob-
served Sigma must be at least 4.35 Sigma higher 
than the desired Assured Sigma. For example, to 
assure a long-term quality of < 3.4 DPM (Assured 
Sigma = 4.5), the Observed Sigma should be ≥ 
8.85 (i.e. 4.5 + 4.35). Recently Erna Lenters-Westra 
and Emma English have evaluated 3 new HbA1c 
methods - here called methods A, B, and C - and 
have determined their Sigmas as 8.6, 6.9, and 3.3, 
respectively (9). Given the TF-HbA1c goals of 2 and 
4 Sigma respectively for routine application and 
clinical trials, method A can be controlled easily by 
1:3s N1 in both routine laboratories and clinical tri-
als to provide both Assured Sigmas of 2 and 4, re-
spectively. Method B can still be controlled by 1:3s 
N1 in the routine application, but in clinical trials, it 
should be controlled by a more stringent SQC e.g. 
1:3s N4. Method C with Sigma of 3.3 is not accept-
able for clinical trials because its quality is less than 
the target of 4 Sigma. On the other hand, control-
ling this method to provide an Assured Sigma of 2 
in routine laboratory needs applying a complex 
multi-rule SQC such as 1:3s/2of3:2s/R:4s/3:1s/6x 
N6, which, in addition to high expense and trou-
ble, has a Pfr of 5%.
The 1:3s/2of3:2s/R:4s/3:1s/6x N6 SQC procedure, 
one of the toughest practical SQCs, needs a sys-
tematic shift of 1.7 Sigma to reach Ped = 90%. So, 
to assure less than 5% erroneous results in long-
term, the least needed Observed Sigma is 3.35 Sig-
ma (1.65 + 1.7). Therefore, although methods with 
Observed Sigmas of 1.65 to 3.35 are theoretically 
acceptable, such methods are not practically con-
trollable. This is the basis for the advice frequently 
emphasized by J. O. Westgard that methods with 
qualities of < 3 Sigma should not be used in medi-
cal laboratories because these methods cannot be 
controlled by practically affordable SQC proce-
dures (5). Similarly, with higher goals of Assured 
Sigma, the least Observed Sigma that can be con-
trolled by these SQCs must be again 1.7 Sigma 
higher than the goal. For example, with the 4 Sig-
ma goal set by TF-HbA1c for clinical trials, a HbA1c 
method must have an Observed Sigma of ≥ 5.7 (4 
+ 1.7) to be controllable in clinical trials. Thus, al-
though a HbA1c method with Observed Sigma of 
e.g. 4.5 is theoretically acceptable for clinical trials, 
there is no practical SQC to assure a long-term Sig-
ma of 4 suggested by TF-HbA1c. To repeat J. O. 
Westgard advice, HbA1c methods with qualities of 
< 5.7 Sigma should not be used in clinical trials.
Interestingly, the 1.7 Sigma shift needed for 
1:3s/2of3:2s/R:4s/3:1s/6x N6 is close to the 1.5 Sig-
ma shift assumed in the Six Sigma. The important 
difference is that the Six Sigma assumes that the 
1.5 shift is the worst scenario even with no QC ap-
plied, while the 1.7 shift in medical laboratory is 
the best scenario with applying the most stringent 
SQC. If looser SQCs are applied, shifts larger than 
1.7 Sigma is expected; and with no QC, shifts of 
any size are expected.  
Since Sigma values are related to the area under 
the curve of the Gaussian distribution, it maybe 
seem that Sigma values cannot be treated as line-
ar parameters, e.g. in the equation Sigma(Assured) = 
Sigma(Observed) - Sigma(SQC). Given the Sigma value 
is nothing but the number of the SDs that fit in the 
distance between mean and the nearest TEa limit, 
any value that is in the SD units can be added to or 
subtracted from Sigma as linear parameters. For 
example, if a bias of 2 SD happens for a bias-free 
5-Sigma method, then the method becomes a 
3-Sigma method because the shift has subtracted 
2 SDs from the original Sigma; simply calculated as 
5 – 2 = 3. It is the same for changes in the impreci-
sion; for example, if the imprecision of a 6-Sigma 
method triples, then the method becomes a 2-Sig-
ma method (calculated as 6 ÷ 3 = 2); and if the im-
precision of this method halves, the new Sigma 
becomes 12 (calculated as 6 × 2 = 12). The thing 
that cannot be treated as linear parameter is the 
defect rate, because there isn’t a linear relation be-
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tween Sigma value and defect rate. For example, if 
Sigma is halved, it cannot be concluded that the 
defect rate is also halved, but the new defect rate 
must be calculated as the area under the Gaussian 
curve corresponding the new Sigma. 
Coskun et al. have criticized the Westgard ap-
proach to Sigma calculation (10). They claim that 
the Westgard approach is one-sided and 50% of 
data are not included in the performance calcula-
tion, therefore the Sigma level is lower than the 
actual Sigma; and they recommend that the actual 
Sigma level can be calculated using the area under 
the curve, what they call ‘a new approach to calcu-
lating Sigma metric’ (10). The fact is that Sigma val-
ues and defect rates are anywhere converted to 
each other using the area under the Gaussian 
curve, and the approach recommended by Coskun 
et al. is not something new. In the Westgard ap-
proach, the Sigma scores are converted to the de-
fect rates using Sigma tables that are produced 
based on the area under the curve, and, therefore, 
by no means 50% of the data are missed from the 
performance calculation. The problem with the 
Coskun et al. is that they have confused the short-
term/long-term concept with the one-sided/two-
sided concept. The reason that the calculated de-
fect rates in the Coskun et al. calculations are sig-
nificantly lower than the Westgard approach is 
that they have neglected the 1.5 SD subtraction. 
Coskun et al. in fact, have calculated the short-
term/Observed defect rates, whereas in the West-
gard approach (that is in compliance with the Six 
Sigma approach) 1.5 SD is subtracted from the cal-
culated Sigma and therefore the long-term/As-
sured defect rates are calculated which are higher 
than the short-term/Observed defect rates.
To conclude, long-term Sigma is a measure of the 
reliability of laboratory results. In contrast to the Six 
Sigma methodology, the long-term quality in the 
medical laboratory is not arbitrarily 1.5 Sigma less 
than the short-term quality, but is determined by 
the shift needed for the applied SQC to reject the 
performance with a high Ped. In other words, the 
long-term quality of analytical performance in the 
medical laboratory is the quality that can be as-
sured with the applied SQC. This vein, long-term 
Sigma can be called Assured Sigma. Given the Six 
Sigma tables present long-term defect rates assum-
ing 1.5 Sigma shift, referring to these tables to de-
termine the long-term defect rate of analytical per-
formance in the medical laboratory will be mislead-
ing. To calculate long-term defect rate of analytical 
performance, laboratorians must calculate the shift 
needed for the SQC to reach a Ped of 90%, 
Sigma(SQC); subtract Sigma(SQC) from Observed Sig-
ma to calculate Assured Sigma; and finally calculate 
long-term defect rate as P (z > Assured Sigma). 
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